LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity
Akshay T. Krishnamurty, Justin A. Shyer, Minh Thai, Vineela Gandham, Matthew B. Buechler, Yeqing Angela Yang, Rachana Pradhan, Amber W. Wang, Patricia L. Sanchez, Yan Qu, Beatrice Breart, Cécile Chalouni, Debra Dunlap, James Ziai, Justin Elstrott, Neelie T. Zacharias, Weiguang Mao, Rebecca K. Rowntree, Jack Sadowsky, Gail D. Lewis Phillips, Thomas H. Pillow, Barzin Y. Nabet, Romain Banchereau, Lucinda Tam, Roger Caothien, Natasha Bacarro, Merone Roose‐Girma, Zora Modrušan, Sanjeev Mariathasan, Sören Müller, Shannon J. Turley
Abstract
Abstract Recent single-cell studies of cancer in both mice and humans have identified the emergence of a myofibroblast population specifically marked by the highly restricted leucine-rich-repeat-containing protein 15 (LRRC15) 1–3 . However, the molecular signals that underlie the development of LRRC15 + cancer-associated fibroblasts (CAFs) and their direct impact on anti-tumour immunity are uncharacterized. Here in mouse models of pancreatic cancer, we provide in vivo genetic evidence that TGFβ receptor type 2 signalling in healthy dermatopontin + universal fibroblasts is essential for the development of cancer-associated LRRC15 + myofibroblasts. This axis also predominantly drives fibroblast lineage diversity in human cancers. Using newly developed Lrrc15– diphtheria toxin receptor knock-in mice to selectively deplete LRRC15 + CAFs, we show that depletion of this population markedly reduces the total tumour fibroblast content. Moreover, the CAF composition is recalibrated towards universal fibroblasts. This relieves direct suppression of tumour-infiltrating CD8 + T cells to enhance their effector function and augments tumour regression in response to anti-PDL1 immune checkpoint blockade. Collectively, these findings demonstrate that TGFβ-dependent LRRC15 + CAFs dictate the tumour-fibroblast setpoint to promote tumour growth. These cells also directly suppress CD8 + T cell function and limit responsiveness to checkpoint blockade. Development of treatments that restore the homeostatic fibroblast setpoint by reducing the population of pro-disease LRRC15 + myofibroblasts may improve patient survival and response to immunotherapy.